Browse All
Displaying 1 - 1 of 1
Author:Naismith, Robert T. Cohen, Jeffrey A. Bar-Or, Amit Comi, Giancarlo Selmaj, Krzysztof W. Hartung, Hans-Peter Sheffield, James K. Krakovich, Anthony Cheng, Chun-Yen Reardon, Jennifer Riolo, Jon V. Silva, Diego Cree, Bruce A. C.
Session Name:P7: MS Therapeutics 1
Topic:MS and Inflammatory Disease
Program Number:P7.013
Author Institution:Washington University School of MedicineWashington University School of Medicine, St Louis, Missouri, St Louis, MO Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of PennsylvaniaCenter for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelph Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Olsztyn, Poland Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf Germany Brain and Mind Centre, University of Sydney, Australia Department of Neurology, Medical University of Vienna, Austria and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Germany Bristol Myers Squibb, Princeton, New Jersey, Princeton, PA Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ Weill Institute for Neurosciences, Department of Neurology, University of California San FranciscoWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA
